November 2024

Efficacy signals observed will not achieve ESSA’s target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens  A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy data

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: